Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure. Issue 13 (7th July 2020)

• Record Type: Journal Article
• Authors: Tummalapalli, Sri Lekha; Zelnick, Leila R.; Andersen, Amanda H.; Christenson, Robert H.; deFilippi, Christopher R.; Deo, Rajat; Go, Alan S.; He, Jiang; Ky, Bonnie; Lash, James P.; Seliger, Stephen L.; Soliman, Elsayed Z.; Shlipak, Michael G.; Bansal, Nisha
• Other Names: Appel Lawrence J. investigator.; Feldman Harold I investigator.; Go Alan S. investigator.; Rao Panduranga S. investigator.; Rahman Mahboob investigator.; Townsend Raymond R. investigator.
• Is Part Of: Journal of the American Heart Association. Volume 9:Issue 13(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-07
• Subjects: cardiac biomarkers -- heart failure -- quality of life; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.119.014385
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a measure of heart failure (HF) health status. Worse KCCQ scores are common in patients with chronic kidney disease (CKD), even without diagnosed heart failure (HF). Elevations in the cardiac biomarkers GDF‐15 (growth differentiation factor‐15), galectin‐3, sST2 (soluble suppression of tumorigenesis‐2), hsTnT (high‐sensitivity troponin T), and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) likely reflect subclinical HF in CKD. Whether cardiac biomarkers are associated with low KCCQ scores is not known. Methods and Results: We studied participants with CKD without HF in the multicenter prospective CRIC (Chronic Renal Insufficiency Cohort) Study. Outcomes included (1) low KCCQ score <75 at year 1 and (2) incident decline in KCCQ score to <75. We used multivariable logistic regression and Cox regression models to evaluate the associations between baseline cardiac biomarkers and cross‐sectional and longitudinal KCCQ scores. Among 2873 participants, GDF‐15 (adjusted odds ratio 1.42 per SD; 99% CI, 1.19–1.68) and galectin‐3 (1.28; 1.12–1.48) were significantly associated with KCCQ scores <75, whereas sST2, hsTnT, and NT‐proBNP were not significantly associated with KCCQ scores <75 after multivariable adjustment. Of the 2132 participants with KCCQ ≥75 at year 1, GDF‐15 (adjusted hazard ratio, 1.36 per SD; 99% CI, 1.12–1.65), hsTnT (1.20; 1.01–1.44), and NT‐proBNP (1.30; 1.08–1.56) were associated with incident decline in KCCQ to <75 after multivariable adjustment, whereas galectin‐3 and sST2 did not have significant associations with KCCQ decline. Conclusions: Among participants with CKD without clinical HF, GDF‐15, galectin‐3, NT‐proBNP, and hsTnT were associated with low KCCQ either at baseline or during follow‐up. Our findings show that elevations in cardiac biomarkers reflect early symptomatic changes in HF health status in CKD patients.